跳至主要内容
临床试验/NL-OMON48148
NL-OMON48148撤回不适用

Effect of sodium oxybate on brown adipose tissue activity in narcolepsy - Sodium oxybate and brown adipose tissue in narcolepsy

eids Universitair Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Narcolepsy type 1 based on ICSD-3 criteria.
  • 2. *18 and <40 years of age.
  • 3. White Caucasian descent.
  • 4. Clinical indication for sodium oxybate treatment.
  • 5. BMI * 27 kg/m2, Healthy controls:
  • 1. Age-, gender- and BMI-match with patient.

排除标准

  • Patients and healthy controls:
  • 1. Smoking.
  • 2. Renal, hepatic or endocrine disease.
  • 3. Previous use of sodium oxybate.
  • 4. Use of medication known to influence glucose and/or lipid metabolism or
  • brown adiposue tissue activity (e.g. *-adrenergic receptor blockers).
  • 5. Participation in an intensive weight-loss program or vigorous exercise
  • program during the year before the start of the study.
  • 6. Contraindications for sodium oxybate treatment.
  • 7. Contraindications for undergoing an MRI scan:
  • - Presence of non-MR safe metal implants or objects in the body.
  • - Pacemaker, neurostimulator, hydrocephalus pump, drug pump, non-removable
  • hearing aid, large recent tattoos.
  • - Claustrophobia
  • - Tinnitus or hyperacusis

研究者

相似试验